Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients

• 作 者: Bo Jia Yuankai Shi Suyi Kang S
• 机 构: DepartmentofMedicalOncology,DepartmentofRadiationOncology,DepartmentofMedicalRecordLibrary
• 出 处: 中国癌症研究：英文版
• 发表日期: 2015年5期
• 关键词: B细胞淋巴瘤 单核细胞 患者 单抗 放射治疗 多变量分析 PFS 放疗 Diffuse large B-cell lymphoma （DLBCL） stage
• 基金项目: Departments of Medical Oncology and Radiation Oncology for study collaboration,Department of Medical Record Library for medical record provision,thank Chinese Society of Clinical Oncology(CSCO) for pa

Background:The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma(DLBCL) remains to be defined.We aimed to compare CHOP plus rituximab(R-CHOP) with CHOP alone and determine the value of radiotherapy i